Denmark-based dermatology specialist LEO Pharma A/S has announced positive outcomes for its drug candidate Enstilar (LEO 90100) in a Phase III clinical trial conducted in China. The trial focused on evaluating Enstilar as a potential treatment for Chinese patients with stable plaque psoriasis.
The primary objective of the study was to assess the comparative efficacy of Enstilar against Kyowa Kirin’s Daivobet (calcipotriol/betamethasone dipropionate) ointment in terms of the severity and extent of stable plaque psoriasis. The secondary objective was to evaluate the safety profile of the treatment. The topline results indicated that Enstilar demonstrated superior efficacy to Daivobet ointment in achieving the primary objective. Following these results, LEO Pharma is preparing for a market approval filing in China, a market with an estimated 7 million individuals suffering from plaque psoriasis.- Flcube.com
